A prospective multicenter study of intermittent chemotherapy with docetaxel and prednisolone for castration-resistant prostate cancer.

CONCLUSIONS: Intermittent docetaxel and prednisolone therapy might be a feasible treatment option for castration-resistant prostate cancer with comparable outcome and successful chemotherapy holidays. PMID: 26962246 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26962246?dopt=Abstract

Source: Clinical Prostate Cancer - March 8, 2016 Category: Cancer & Oncology Authors: Narita S, Koie T, Yamada S, Orikasa K, Matsuo S, Aoki H, Ishidoya S, Hoshi S, Tsuchiya N, Ohyama C, Arai Y, Habuchi T Tags: Jpn J Clin Oncol Source Type: research